68 related articles for article (PubMed ID: 24369188)
1. PSA levels in patients on hemodialysis treatment.
García-Sánchez C; Corchuelo-Maillo C; Congregado-Ruiz CB; Ocón-Revuelta EM; Osman-García I; Conde-Sánchez JM; Medina-López RA
Arch Esp Urol; 2013 Dec; 66(10):939-44. PubMed ID: 24369188
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening with prostate-specific antigen in hemodialysis patients.
Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T
Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492
[TBL] [Abstract][Full Text] [Related]
3. Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen?
Danişman A; Kiliç S; Kukul E; Yakupoğlu G; Güntekin E; Baykara M; Sevük M
Eur Urol; 2000 May; 37(5):579-81. PubMed ID: 10765097
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer using prostate-specific antigen testing in Japanese men on hemodialysis.
Kurahashi T; Miyake H; Shinozaki M; Oka N; Takenaka A; Hara I; Matsumura Y; Fujisawa M
Int Urol Nephrol; 2008; 40(2):345-9. PubMed ID: 17619159
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels.
Tzanakis I; Kazoulis S; Girousis N; Kagia S; Spandidakis V; Karefillakis N; Georgila M; Cristoulakis I; Hatzilias P; Kallivretakis N
Nephron; 2002 Feb; 90(2):230-3. PubMed ID: 11818714
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of total and free prostate specific antigen in men on hemodialysis.
Sasagawa I; Kubota Y; Hayami S; Adachi M; Nakada T; Miura H; Imai K
J Urol; 1998 Jul; 160(1):83-5. PubMed ID: 9628610
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of prostate specific antigen in men on hemodialysis.
Wolff JM; Ting O; Borchers H; Rohde D; Jakse G
Anticancer Res; 2000; 20(6D):5191-3. PubMed ID: 11326693
[TBL] [Abstract][Full Text] [Related]
8. Effect of terminal renal failure on the ratio of free to total prostate-specific antigen.
Douville P; Tiberi M
Tumour Biol; 1998; 19(2):113-7. PubMed ID: 9486562
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
Laguna Pes MP; Guinda Sevillano C; Zazo Romojaro A; Domínguez J; García Luzón A; Borrego Hernando J; Gimeno Collado A
Arch Esp Urol; 2000 May; 53(4):333-41. PubMed ID: 10900763
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
Horninger W; Volgger H; Rogatsch H; Strohmeyer D; Steiner H; Hobisch A; Klocker H; Bartsch G
J Urol; 2001 Apr; 165(4):1143-5. PubMed ID: 11257656
[TBL] [Abstract][Full Text] [Related]
11. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
12. Saturation biopsies for prostate cancer detection: effectiveness, safety and predictive factors.
Utrera NM; Sánchez AT; Rodríguez-Antolín A; Martín-Parada A; Lora D; Passas J; González RD
Arch Esp Urol; 2011 Jun; 64(5):421-6. PubMed ID: 21705814
[TBL] [Abstract][Full Text] [Related]
13. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study.
Wada Y; Nakanishi J; Takahashi W; Kai N; Nakayama Y; Yamashita Y; Honda J; Ueda S
BJU Int; 2006 Oct; 98(4):794-7. PubMed ID: 16978274
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
Chakraborty L; Ahmed AN; Paul BK; Haque A; Ara A; Nabi S; Nessa M
Mymensingh Med J; 2012 Jan; 21(1):98-102. PubMed ID: 22314462
[TBL] [Abstract][Full Text] [Related]
15. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
16. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
17. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
18. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤ 15 ng/ml and normal digital rectal examination: a 10-year prospective follow-up study of 427 consecutive patients.
Mohamed ZK; Dominguez-Escrig J; Vasdev N; Bharathan B; Greene D
Urol Oncol; 2013 Nov; 31(8):1489-96. PubMed ID: 22591749
[TBL] [Abstract][Full Text] [Related]
20. Shift of the f/t-PSA quotient in relation to renal insufficiency: consequences for the early detection of prostate carcinoma in patients with terminal renal failure.
Fischer K; Hamza A; Wicht A; Loertzer H; Fornara P
Anticancer Res; 2007; 27(4A):1945-8. PubMed ID: 17649801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
